Illumina MiSeq i100Plus sequencing system
Type: Forecast
Overview
Description
PA #2 6/16 approved
The purpose of the request is to purchase a new model desktop genomic sequencing system from Illumina that has better technology and build, higher throughput, greater efficiency and accuracy, and less cost per genome compared to the older models. The new model of sequencing instrument shall assist the OAMT scientists on the in-silico design and development of all FDA sequencing applications for foodborne pathogens (bacteria such as Salmonella spp., Listeria monocytogenes and STEC, and viruses and parasites). We will also utilize the instrument to develop and optimize next generation sequencing laboratory protocols and to compare new applications (such as Targeted Amplicon Sequencing) with other genomic methods like whole genome and metagenome sequencing. One instrument for MOD1 (DFES) & one instrument for CPK1 (DFSG) & one instrument for Moffett (DFPST - unfunded)
Est. Value
Min: $25,000
Max: $250,000
Max: $250,000
Est. Award Date
4/1/2026
Source Est. Solicitation Date
2/1/2026
Set Aside
To be determined
Forecast Type
New
Forecast Source
Health and Human Services
Food and Drug Administration is forecasted to issue a new procurement for Illumina MiSeq i100Plus sequencing system around 4/1/2026 worth up to $250,000.
Agency
Source Level 1 Agency
Health and Human Services
Source Level 2 Agency
Food and Drug Administration
Contacts
Point of Contact
HFP ACQUISITION LIAISON   Profile
Point of Contact Email
Small Business Offices
Potential Bidders and Partners
Similar Active Opportunities
Additional Detail
Date Published
2/12/26